Financial Performance - The company's operating revenue for Q1 2023 was CNY 406,964,645.20, representing a 1.26% increase compared to CNY 401,892,660.83 in the same period last year[19]. - The net profit attributable to shareholders for Q1 2023 was CNY 125,032,072.76, reflecting a 10.05% increase from CNY 113,615,316.77 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 123,163,392.59, up 16.13% from CNY 106,060,530.46 in the previous year[19]. - Basic earnings per share for Q1 2023 were CNY 0.1423, a 10.05% increase from CNY 0.1293 in the previous year[19]. - Total revenue for the period was ¥406,964,645.20, slightly up from ¥401,892,660.83, indicating a growth of about 1.67%[40]. - Total operating costs decreased to ¥267,578,566.10 from ¥284,682,327.54, representing a reduction of approximately 6.02%[40]. - Total comprehensive income attributable to the parent company reached ¥130,433,697.15, up from ¥69,208,940.24 in the previous period[35]. Cash Flow - The net cash flow from operating activities improved significantly to CNY 845,565.26, compared to a negative CNY 147,343,968.04 in the same period last year, marking a 100.57% increase[19]. - Net cash flow from operating activities increased by 100.57% compared to the same period last year, mainly due to an increase in cash received from sales and a decrease in procurement payments[22]. - Cash and cash equivalents increased by 1,015.90% compared to the same period last year, mainly due to an increase in cash received from sales and a decrease in procurement payments[25]. - Operating cash inflow totaled ¥423,890,182.85, compared to ¥363,423,311.45 in the previous period, reflecting a growth of approximately 16.67%[36]. - The net increase in cash and cash equivalents was $111,605,216.10, compared to a decrease of $12,185,346.62 in the previous period[43]. - The ending balance of cash and cash equivalents was $1,522,704,200.70, up from $1,036,867,627.17 in the previous period[43]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,350,645,162.64, a 1.08% increase from CNY 3,314,919,654.11 at the end of the previous year[19]. - The equity attributable to shareholders increased to CNY 2,787,833,990.48, up 5.23% from CNY 2,649,221,170.17 at the end of the previous year[19]. - Current liabilities decreased to ¥497,809,507.27 from ¥600,447,530.91, showing a reduction of about 17.09%[39]. - Non-current assets totaled ¥832,549,115.25, a slight increase from ¥827,225,875.22[39]. Shareholder Information - The company reported a total of 18,805 common shareholders at the end of the reporting period[12]. - The largest shareholder, Tian Ming, holds 60.90% of the shares, amounting to 537,462,900 shares[12]. Government Subsidies and Other Financials - The company recognized government subsidies amounting to CNY 1,332,818.23 during the reporting period[2]. - Financial expenses increased by 91.77% compared to the same period last year, mainly due to an increase in exchange losses[22]. - Interest income increased by 609.67% compared to the same period last year, mainly due to an increase in interest income from US dollar deposits[22]. - Accounts receivable financing decreased by 39.45% compared to the beginning of the period, primarily due to a reduction in bank acceptance bills not endorsed at the end of the period[22]. - Prepayments decreased by 69.38% compared to the beginning of the period, mainly due to a reduction in advance payments for materials[22]. - Other receivables increased by 127.62% compared to the beginning of the period, mainly due to an increase in unreimbursed deposits and service fees at the end of the period[22]. Audit Information - The company’s first quarter report was not audited[44].

Financial Performance - The total cash inflow from operating activities for 2022 was ¥2,219,335,436.48, representing a year-on-year increase of 5.62% compared to ¥2,101,155,035.15 in 2021[8]. - The company's revenue for the year 2022 was approximately ¥18.98 million, with a net profit of ¥827,168.61[49]. - The company aims for a revenue growth of no less than 17% in 2023 compared to 2022[51]. - The company reported a total of ¥10,950,199.72 in investment income, accounting for 1.31% of total profit, primarily from bank financial product investments[9]. - The total distributable profit for the company was 769,123,482.00 CNY[102]. Cash Flow and Investments - The net cash flow from investing activities increased by 58.67% year-on-year, primarily due to a reduction in cash management principal payments[9]. - The company reported a total of 911,070,930.61 RMB invested in fundraising projects by December 31, 2022[43]. - As of December 31, 2022, the remaining balance of raised funds was 19,276,416.98 RMB[43]. - The company utilized 96,000,000.00 RMB of the raised funds during the 2022 fiscal year[43]. - The company has cumulatively distributed over ¥3 billion in cash dividends since its listing[70]. Operational Efficiency and Management - The company has established a complete management system for independent operations, including financial management and quality control[31]. - The company is focusing on enhancing management efficiency through digital and intelligent upgrades[52]. - The company has implemented a multi-level management system centered on customer service to optimize management rules and assessment mechanisms[52]. - The company plans to further streamline and improve its management system and operational mechanisms in response to external and internal changes[55]. - The company has maintained effective internal financial reporting controls, with no major deficiencies identified[135]. Employee Development and Compensation - The company will continue to emphasize talent development and optimize its internal and external training systems to enhance employee capabilities[22]. - The company emphasizes the importance of competitive compensation and career development to retain core talent amidst industry competition[24]. - The total number of employees at the end of the reporting period was 1,307, with 539 being technical staff and 216 in sales[97]. - The company has implemented a comprehensive salary system based on job value and performance, ensuring competitive compensation for employees[99]. - A total of 75,400 shares of restricted stock were granted to 321 incentive targets as part of the stock incentive plan[103]. Environmental and Social Responsibility - The company is committed to reducing carbon emissions and has integrated low-carbon practices into daily management[65]. - The company has not experienced any major environmental pollution incidents during the reporting period[66]. - The company strictly adheres to labor laws and has established comprehensive employment management systems to ensure employee welfare and rights[71]. - The company emphasizes the protection of shareholder and creditor rights through transparent governance and information disclosure[68]. Shareholder Engagement and Governance - The company has implemented effective communication channels to ensure fair information access for all shareholders[29]. - The company has held two shareholder meetings during the reporting period, adhering to legal and procedural requirements[28]. - The company’s board meetings were held regularly, with significant decisions made regarding quarterly reports and stock incentive plans[91]. - The company has a performance assessment target for the restricted stock incentive plan for the years 2022-2023[107]. - The company emphasizes a profit distribution mechanism that balances investor returns and sustainable development[121]. Product Development and Market Strategy - The company is focused on technology innovation and product iteration to increase market share and achieve stable revenue growth[25]. - The company has formed a product lineup for oral CBCT, which is widely used in various clinical applications, enhancing its market competitiveness[137]. - The company is actively pursuing industrial internet projects in the food processing and oral medical sectors, aiming to build an industrial internet ecosystem[139]. - The company has developed multiple series of products in the field of optoelectronic identification technology, with some technologies reaching industry-leading levels[163]. Financial Audits and Compliance - The internal control evaluation report indicates that 100% of the total assets and operating income of the evaluated units are included in the consolidated financial statements[82]. - There were no significant defects found in the internal control audit report, and the company received a standard unqualified opinion[86]. - The company has not identified any significant deficiencies in non-financial reporting internal controls as of the evaluation report benchmark date[162]. - The company has implemented internal control system improvements and strengthened internal audit supervision to enhance operational compliance and risk management[161].

证券代码：002690 证券简称：美亚光电 公告编号：2023-010 合肥美亚光电技术股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 投资者依据提示，授权登入"美亚光电投资者关系"小程序，即可参与交流。 出席本次年度报告说明会的人员有：副董事长兼总经理沈海斌女士、副总经 理兼财务总监张浩先生、董事会秘书程晓宏先生、独立董事储育明先生。 欢迎广大投资者积极参与。 特此公告。 1 合肥美亚光电技术股份有限公司董事会 2023年3月31日 2 合肥美亚光电技术股份有限公司（以下简称"公司"）已于2023年3月31日 披露《2022年年度报告》全文及摘要，为使投资者及时了解公司年度经营情况， 公司定于2023年4月12日下午15:00-17:00在"美亚光电投资者关系"小程序举办 2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者 可登录"美亚光电投资者关系"参与互动。为广泛听取投资者的意见和建议，提 前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信中搜索"美亚 ...

Group 1: Strategic Collaborations - The company signed a strategic cooperation framework agreement with the Shanghai Bone Tumor Research Institute on November 3, 2015, aimed at advancing new treatment technologies for bone and soft tissue tumors [3] - The collaboration focuses on the development of high-end medical imaging equipment and remote diagnosis services, with specific cooperation details to be announced later [3] Group 2: Product Development and Market Outlook - The X-ray packaging food detection series has matured and is currently on the market, with significant potential due to increasing food safety demands [4] - The company expects to meet its sales targets for the X-ray dental CT diagnostic machine series in 2015, with a stable market competition landscape [4][5] - The company is actively upgrading existing products while expanding into other specialized high-end medical imaging equipment [5] Group 3: Financial Insights - The increase in accounts receivable is primarily due to the implementation of credit sales for export customers, with cooperation from the China Export Credit Insurance Corporation to mitigate risks [4]

Group 1: Export and Sales Performance - The company has strengthened its overseas export efforts, with export growth expected to exceed 60% in 2014 [2] - The sales model combines direct sales and distribution, with direct sales accounting for 60% of total sales [2] Group 2: Product Development and Market Opportunities - The color sorting machine series has maintained stable growth due to factors such as the need for equipment updates every 3-5 years and increasing demand for quality in grain products [2] - The company is actively expanding both domestic and international markets, particularly in the rapidly growing export of color sorting machines [2] - Continuous application of new technologies enhances product value [2] Group 3: Financial Strategy and Cash Utilization - The company plans to invest in R&D for new technologies and products while seeking partnerships and acquisitions to enhance core competitiveness [3] - Current after-sales service revenue is low, primarily from equipment consumables and remote service fees [3] Group 4: Future Trends in Dental Equipment - The aging population and increasing awareness of oral health in China are driving demand for dental services, positioning the company's dental X-ray CT machine for significant market potential [3]

Group 1: Company Developments - The company has completed the research and development of orthopedic CT series equipment, currently in the testing and clinical phase, and plans to launch it after obtaining regulatory production licenses [2] - A strategic cooperation agreement has been signed with the Hefei Institute of Physical Science, aiming to enter the high-end precision radiotherapy industry, particularly proton therapy [3] - The company has undertaken a national major scientific instrument project, developing an infrared mass spectrometry device for early liver cancer detection [3] Group 2: Shareholder Actions - Company executives completed a stock purchase plan on November 16, 2015, with a total investment exceeding 10 million yuan, reflecting confidence in the company's future [3] - Since its listing, the shareholding of directors, supervisors, and senior management has remained stable without significant fluctuations [3] Group 3: Market Outlook - The industrial testing market includes various sectors such as ordinary industrial product testing, food safety, environmental testing, and security checks, with significant future demand expected due to increased safety regulations [4] - The company aims for sales revenue from the industrial testing sector to reach 30% of total revenue in the future [4] Group 4: Financial Strategy - The company plans to increase investments in high-end medical imaging and industrial testing, considering mergers or restructuring to enhance competitiveness and profitability [4]

Group 1: Competitive Advantages - The company's oral CT diagnostic machines are independently developed, possessing complete intellectual property rights, and offer lower radiation and higher clarity compared to similar products domestically and internationally [2][3]. - The company's after-sales service is quick to respond, more convenient, and cost-effective, with product prices being more competitive than foreign counterparts [3]. Group 2: Medical Field Planning - The company has a three-step plan for the medical field: short-term focus on high-end specialized imaging equipment like oral and skeletal CTs to replace imports; mid-term research in cancer detection and treatment; and long-term collaboration with international medical companies to develop more domestic medical products [3][4]. Group 3: Market Response and New Products - Following the launch of the new generation color selection machine equipped with advanced CCD technology and big data internet technology, the product received positive feedback and strong sales performance from both domestic and international clients [4]. - The aflatoxin detection equipment has entered the pilot testing stage and will be gradually introduced to the market after continuous upgrades [4]. Group 4: Future Mergers and Acquisitions - Since transitioning to the medical field in 2012, the company has developed mature high-end oral imaging products and plans to continue investing in this area, with potential for mergers or restructuring to enhance core competitiveness and expand market reach [4]. Group 5: Export Growth Trends - The company has significantly increased its overseas exports, with products now reaching over 80 countries and regions, and expects to maintain rapid growth in export business, with color selection machine export revenue projected to account for over half of total revenue in the future [5].

Group 1: Sales Performance - The company's self-developed oral X-ray CT diagnostic machine series has broken foreign monopolies and filled domestic gaps since its market launch in the second half of 2012, receiving enthusiastic welcome from domestic dental medical institutions, especially private dental hospitals/clinics, leading to rapid sales revenue growth [1][2] - With further market expansion and increasing societal demand for dental treatment, the company expects continued strong sales growth for its oral X-ray CT diagnostic machine series in the coming years [2] Group 2: R&D in High-end Medical Imaging - Following the successful launch of the oral X-ray CT diagnostic machine series, the company has increased its R&D investment in high-end medical imaging, successfully developing several new high-end medical imaging devices, including a self-developed skeletal CT device currently in clinical validation [2] - The company aims to replace imports and fill domestic gaps in high-end medical imaging equipment, with plans to continue increasing R&D investment in this field to develop more market-demanded products [2] Group 3: Strategic Cooperation - The company has signed a strategic cooperation framework agreement with the Hefei Research Institute of the Chinese Academy of Sciences, aimed at promoting the high-end precision radiotherapy industry represented by proton therapy and related medical equipment [3] - The cooperation will focus on R&D and manufacturing of high-end medical imaging equipment, high-end precision radiation therapy systems, medical imaging big data, and remote diagnosis services, which will enhance the company's industry layout and overall competitiveness [3] Group 4: Future Investment Directions - The company plans to increase investments in high-end medical imaging and industrial inspection fields while ensuring continuous innovation and stable development of its core color selection machine business [4] - Future mergers and acquisitions must enhance the company's core competitiveness and benefit product sales channels and market expansion [4]

Group 1: Export Business - The company's export business has seen a growth rate exceeding 50% in the first half of 2015 [2] - The international trade department has exported products to over 80 countries and regions, with continuous growth expected in 2015 [3] Group 2: Cash Utilization Plans - The company plans to invest more in high-end medical imaging and industrial inspection fields, considering mergers and acquisitions that enhance core competitiveness and expand sales channels [3] Group 3: Collaboration with Research Institutions - The company has signed a strategic cooperation framework agreement with the Hefei Institute of Material Science, aiming to advance high-end precision radiotherapy and related medical equipment industries [3][4] Group 4: New Product Development in Medical Field - The company is developing a series of high-end medical imaging devices based on core imaging recognition technology, with the skeletal CT currently in clinical validation and expected to launch by the second half of next year [4] Group 5: Sales Expectations for Dental CT - The sales of the oral X-ray CT diagnostic series have shown a growth rate exceeding 90% in the first half of the year, with continued rapid growth expected throughout the year [4]

Financial Performance - The company's operating revenue for Q3 2022 was ¥595,377,005.30, representing a 7.75% increase year-over-year, and a total revenue of ¥1,499,638,185.64 for the year-to-date, up 9.21% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥232,660,114.59, a 29.35% increase year-over-year, with a year-to-date net profit of ¥556,932,950.69, up 29.87% compared to the previous year[7] - The basic earnings per share for Q3 2022 was ¥0.2638, reflecting a 29.00% increase year-over-year, with diluted earnings per share also at ¥0.2638[7] - Total operating revenue for the third quarter reached ¥1,499,638,185.64, an increase of 9.2% compared to ¥1,373,223,436.41 in the same period last year[33] - Operating profit increased significantly to ¥649,425,327.79, up from ¥491,479,423.83, marking a growth of 32.1%[33] - Net profit for the quarter was ¥556,932,950.69, compared to ¥428,840,784.02 in the previous year, representing a year-over-year increase of 30.0%[35] - Basic and diluted earnings per share improved to ¥0.6316 from ¥0.4876, indicating a 29.5% increase[35] Assets and Liabilities - The company's total assets at the end of Q3 2022 were ¥3,069,598,624.78, a decrease of 5.63% from the end of the previous year[7] - Total liabilities decreased to ¥616,548,374.71 from ¥747,385,456.79, a reduction of 17.5%[33] - Owner's equity totaled ¥2,453,050,250.07, slightly down from ¥2,505,260,055.55, a decrease of 2.1%[33] - Deferred income tax liabilities decreased to ¥28,734,678.00 from ¥43,874,004.00, a decline of 34.5%[33] Cash Flow - Cash flow from operating activities for the year-to-date was ¥135,518,059.18, showing a significant decline of 61.29% compared to the same period last year[7] - Operating cash inflow for the period was $1,577,436,534.77, an increase from $1,523,750,480.83 in the previous period, reflecting a growth of approximately 3.5%[40] - Cash outflow from operating activities totaled $1,441,918,475.59, compared to $1,173,635,113.83 in the prior period, indicating a significant increase of about 22.9%[40] - Net cash flow from operating activities decreased to $135,518,059.18 from $350,115,367.00, representing a decline of approximately 61.2%[40] - Cash inflow from investment activities was $1,096,982,726.42, down from $1,270,037,161.15, a decrease of about 13.6%[40] - Net cash flow from investment activities increased to $604,077,107.94 from $317,199,532.09, showing a growth of approximately 90.3%[40] - Cash outflow from financing activities was $542,614,400.00, slightly up from $540,800,000.00, reflecting a marginal increase of about 0.3%[43] - The net increase in cash and cash equivalents for the period was $298,102,809.57, compared to $123,689,442.60 in the prior period, indicating a growth of approximately 141.1%[43] - The ending balance of cash and cash equivalents was $1,347,155,783.36, up from $789,055,446.09, representing an increase of about 70.8%[43] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,653[19] - The largest shareholder, Tian Ming, holds 60.95% of the shares, totaling 537,462,900 shares[19] - The top ten shareholders hold a combined 83.87% of the shares, indicating a high concentration of ownership[19] - The company has not disclosed any related party relationships among the top shareholders[22] Expenses and Management - The company reported a 58.93% increase in management expenses year-over-year, mainly due to stock incentive amortization costs[12] - Research and development expenses rose to ¥83,782,971.16, up from ¥76,042,048.84, reflecting a growth of 10.0%[33] Inventory and Receivables - Accounts receivable increased by 57.59% compared to the beginning of the year, primarily due to revenue growth[10] - Inventory grew by 36.67% compared to the beginning of the year, attributed to an increase in raw materials[10] - Accounts receivable increased to ¥309,804,751.36 from ¥196,587,894.40 at the beginning of the year, reflecting a growth of approximately 57.4%[26] - Inventory as of September 30, 2022, is ¥481,780,052.54, up from ¥352,518,141.01 at the beginning of the year, indicating a growth of about 36.5%[26] Other Information - The company is in the process of repurchasing and canceling restricted stock options for departed employees, which was approved by the board and shareholders[23] - The company has also approved adjustments to the reserved restricted stock options for the incentive plan, which are currently being processed[23] - Other comprehensive income after tax showed a loss of ¥84,483,085.63 compared to a gain of ¥129,668,413.02 in the previous year[35] - The third quarter report was not audited, indicating that the financial data has not undergone external verification[44]